ReviewFrontiers in molecular biosciences2021
Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response.
Review in Frontiers in molecular biosciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Understanding the Lymph Node Microenvironment in Metastatic and Non-Metastatic Head and Neck Squamous Cell Carcinoma: A Systematic Review.Journal of personalized medicine · 2026Review
- Tumor-draining lymph nodes respond to immune checkpoint inhibition and orchestrate tumor immune remodeling.Cancer immunology, immunotherapy : CII · 2025Article
- Lymph nodes molecular subtypes unravel lymph nodes heterogeneity and clinical implications in colorectal cancer.Nature communications · 2025Article
- Prognostic Significance, Radiological, and Metabolic Characteristics of Metastatic Lymph Nodes in Resectable Non-Small Cell Lung Cancer Following Neoadjuvant Chemoimmunotherapy.Thoracic cancer · 2025Article
- From trash to treasure: tumor draining lymph nodes as a multi-omics goldmine in cancer therapy.Frontiers in oncology · 2025Review
- Harnessing the power of tumor-draining lymph nodes: unveiling predictive biomarkers for immune checkpoint inhibitor.Exploration of targeted anti-tumor therapy · 2025Review
- Tumor draining lymph nodes connected to cold triple-negative breast cancers are characterized by Th2-associated microenvironment.Nature communications · 2024Article
- Review
- Evaluation of markers of immunity in different metastatic immune microenvironments suggests more suppression within breast to liver metastases in breast cancer.Breast cancer research and treatment · 2024Article
- Tumor-draining lymph nodes: opportunities, challenges, and future directions in colorectal cancer immunotherapy.Journal for immunotherapy of cancer · 2024Review
- Management of locally advanced non-small cell lung cancer: State of the art and future directions.Cancer communications (London, England) · 2024Review
- Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions.Signal transduction and targeted therapy · 2023Review
- Article
- Automated detection of vascular remodeling in tumor-draining lymph nodes by the deep-learning tool HEV-finder.The Journal of pathology · 2022Article
- Cyanine Phototruncation Enables Spatiotemporal Cell Labeling.Journal of the American Chemical Society · 2022Article
- Review
- A roadmap for translational cancer glycoimmunology at single cell resolution.Journal of experimental & clinical cancer research : CR · 2022Review
- Immune-related dissociated response as a specific atypical response pattern in solid tumors with immune checkpoint blockade.Therapeutic advances in medical oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The need for predictive biomarkers that can accurately predict patients who will respond to immune checkpoint inhibitor (ICI) immunotherapies remains a clinically unmet need. The majority of research efforts have focused on expression of immune-related markers on the tumour and its associated tumour microenvironment (TME). However, immune response to tumour neoantigens starts at the regional lymph nodes, where antigen presentation takes place and is regulated by multiple cell types and mechanisms. Knowledge of the immunological responses in bystander lymphoid organs following ICI therapies and their association with changes in the TME, could prove to be a valuable component in understanding the treatment response to these agents. Here, we review the emerging data on assessment of immunological responses within regional lymph nodes as predictive biomarkers for immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.